@article{ref1,
title="Psychiatric Comorbidities in Adults with DiGeorge Syndrome",
journal="Clinical psychopharmacology and neuroscience",
year="2022",
author="Patel, H. and Vadukapuram, R. and Mansuri, Z. and Trivedi, C. and Brar, K.S. and Beg, U. and Patel, J. and Ibrahim, A. and Zafar, M.K.",
volume="20",
number="3",
pages="498-503",
abstract="OBJECTIVE: DiGeorge Syndrome (DGS) is a common multisystem disorder associated with deletions on chromosome 22q11.2. Our objective is to evaluate the psychiatric comorbidities and demographics of patients suffering from DGS in a nationally representative dataset on inpatient hospitalizations. <br><br>METHODS: The Nationwide Inpatient Sample for the year 2005−2017 was used for this study. Data on patients with DiGeorge syndrome were collected by using the International Classification of Diseases code. Univariate and multivariate logistic regression analysis was performed. <br><br>RESULTS: In our study, the average age was 30.4 years (n = 6,563), with 59.9% male, and 61.8% of patients were white. There was a high prevalence of mood disorders (24.7%) and anxiety disorders (16.4%), followed by schizophrenia and other psychotic condition (14.0%). In patients with mood disorders, 8% had Major Depressive Disorder, and 7% had bipolar depression. Overall composite of psychiatric comorbidities was present in 2,959 (45.1%) of patients. The mean length of stay was 6.58 days, and 77% of patients had routine discharge to home. In the adjusted analysis, the average length of stay was 8.6 days vs. 6.7 days (p ＜ 0.001) in patients with and without psychiatry comorbidities. In comparison to routine discharge, patients with psychiatry comorbidities were more likely to be discharged to other healthcare facilities (odds ratio [OR]: 1.28, p ＜ 0.001) and discharged against medical advice (OR: 3.45, p ＜ 0.001). <br><br>CONCLUSION: Patients with DGS have worse outcomes with a higher rate of discharge to other healthcare facilities and a higher rate of being discharged against medical advice. Further large scale randomize studies are indicated. Copyright © 2022, Korean College of Neuropsychopharmacology.<p /><p>Language: en</p>",
language="en",
issn="1738-1088",
doi="10.9758/cpn.2022.20.3.498",
url="http://dx.doi.org/10.9758/cpn.2022.20.3.498"
}